EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice

Jaume Capdevila, Desiree' Deandreis, Cosimo Durante iD, Sophie Leboulleux, Markus Luster, Romana Netea-Maier, Kate Newbold, Susanne Singer, Gerasimos P Sykiotis iD, Beate Bartes, Kate Farnell, Laura Deborah Locati iD

European Thyroid Journal · 10.07.2023 · 12 (5)

DOI: 10.1530/etj-23-0068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Thyroid Journal, erschienen am 10.07.2023. Verfasst von Jaume Capdevila und 11 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain. Hauptthemen laut MEDLINE: Antineoplastic Agents, Thyroid Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Most thyroid cancers of follicular origin have a favorable outcome. Only a small percentage of patients will develop metastatic disease, some of which will become radioiodine refractory (RAI-R). Important challenges to ensure the best therapeutic outcomes include proper, timely, and appropriate diagnosis; decisions on local, systemic treatments; management of side effects of therapies; and a good relationship between the specialist, patients, and caregivers.

Methods

With the aim of providing suggestions that can be useful in everyday practice, a multidisciplinary group of experts organized the following document, based on their shared clinical experience with patients with RAI-R differentiated thyroid cancer (DTC) undergoing treatment with lenvatinib. The main areas covered are patient selection, initiation of therapy, follow-up, and management of adverse events.

Conclusions

It is essential to provide guidance for the management of RAI-R DTC patients with systemic therapies, and especially lenvatinib, since compliance and adherence to treatment are fundamental to achieve the best outcomes. While the therapeutic landscape in RAI-R DTC is evolving, with new targeted therapies, immunotherapy, etc., lenvatinib is expected to remain a first-line treatment and mainstay of therapy for several years in the vast majority of patients and settings. The guidance herein covers baseline work-up and initiation of systemic therapy, relevance of symptoms, multidisciplinary assessment, and patient education. Practical information based on expert experience is also given for the starting dose of lenvatinib, follow-up and monitoring, as well as the management of adverse events and discontinuation and reinitiating of therapy. The importance of patient engagement is also stressed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsThyroid NeoplasmsAdenocarcinomaHumansIodine RadioisotopesPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

differentiated thyroid cancerlenvatinibmanagementradioiodine refractorytoxicity

Substanzen

Antineoplastic AgentsIodine RadioisotopesPhenylurea CompoundslenvatinibQuinolines

Autor:innen und Institutionen

  • Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain.
  • Department of Medical Sciences, Nuclear Medicine Unit, University of Turin, AOU Città della Salute e della Scienza, Turin, Italy.
  • Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Service of Endocrinology, Diabetology, University Hospital Geneve, Geneve, Switzerland.
  • Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.
  • Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Cosimo Durante, Gerasimos P Sykiotis, Laura Deborah Locati

Zitieren

APA

Capdevila, J., Deandreis, D., Durante, C., Leboulleux, S., Luster, M., Netea-Maier, R., Newbold, K., Singer, S., Sykiotis, G. P., Bartes, B., Farnell, K., & Locati, L. D. (2023). Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice. European Thyroid Journal, 12(5). https://doi.org/10.1530/etj-23-0068

Vancouver

Capdevila J, Deandreis D, Durante C, Leboulleux S, Luster M, Netea-Maier R, et al. Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice. European Thyroid Journal. 2023;12(5). doi:10.1530/etj-23-0068

BibTeX
@article{Capdevila2023,
  author = {Capdevila, Jaume and Deandreis, Desiree' and Durante, Cosimo and Leboulleux, Sophie and Luster, Markus and Netea-Maier, Romana and Newbold, Kate and Singer, Susanne and Sykiotis, Gerasimos P and Bartes, Beate and Farnell, Kate and Locati, Laura Deborah},
  title = {Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice},
  journal = {European Thyroid Journal},
  year = {2023},
  volume = {12},
  number = {5},
  doi = {10.1530/etj-23-0068}
}
Kostenlos starten →